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ABSTRACT
Human pluripotent stem cells (hPSCs), including human embryonic stem cells
(hESCs) and induced pluripotent stem cells (iPSCs) hold great promise in the fields of
drug development and regenerative medicine. If iPSCs reprogrammed from patient cells
replicate what is seen in vivo they may be used as a model of disease. A process that is
disrupted in many neurodegenerative diseases is mitochondrial biogenesis. One of
these diseases is amyotrophic lateral sclerosis (ALS), which is characterized by loss of
motor neurons in the brain and spinal cord. Differentiation of hPSCs into motor neurons
offers a way to study a previous unavailable cell type and may further our understanding
of human motor neuron biology. The aims of the present study were to differentiate
motor neurons from hESCs and iPSCs in low oxygen conditions and to explore
mitochondrial biogenesis and electrical maturation during this process. After three
weeks of treatment with retinoic acid and purmorphamine, a sonic hedgehog agonist,
cells increased expression of post mitotic spinal motor neuron markers. One week later
electrophysiological analysis revealed voltage-gated currents and action potential
generation. Mitochondrial biogenesis signaling and expression of respiratory chain
proteins increased with motor neuron differentiation. Respiration analysis revealed a
decrease in glycolysis in motor neurons compared to neural stem cells. Interestingly,
this was not accompanied by an increase in basal respiration or mitochondrial mass.
These findings enhance our understanding of motor neuron mitochondrial biogenesis, a
process impaired in ALS.

CHAPTER ONE: INTRODUCTION
Amyotrophic lateral sclerosis (ALS) is a devastating neurodegenerative disease
characterized by loss of motor neurons in the brain and spinal cord. Despite extensive
study, the mechanisms underlying the pathogenesis of sporadic ALS (sALS) are
currently unknown. Recent studies in our laboratory and others have identified
increased mitochondrial DNA (mtDNA) deletions, decreased electron transport chain
(ETC) subunits, and decreased mitochondrial biogenesis (mitobiogenesis) signaling in
post mortem tissue from sALS patients [1-5]. This bioenergetic impairment may provide
evidence as to why motor neurons are specifically vulnerable in this disease. If ALS
patient cells are unable to maintain a healthy population of mitochondria this could lead
to mitochondrial dysfunction, decreased ATP production, and death of vulnerable cells
like motor neurons. In order to study mitobiogenesis in human motor neurons, the
current project uses human pluripotent stem cells (hPSCs) from healthy patients. The
following chapter will review our current understanding of mitochondrial biogenesis
signaling, differentiation of motor neurons in vivo and how we can replicate this in vitro
in order to study the mechanisms underlying motor neuron death in ALS.

1.1 Mitochondrial biogenesis
Mitochondria play a role in many vital cell functions including ATP synthesis,
calcium homeostasis, reactive oxygen species (ROS) production, and apoptosis. In high
energy requiring post-mitotic tissues like brain, skeletal muscle, and heart, mitochondrial
dysfunction is particularly damaging because cells cannot rid themselves of defective
mitochondria by replicating. These cells rely on mitobiogenesis to produce mitochondrial
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components, and mitophagy, fission and fusion as “quality control” mechanisms to
maintain a population of functional mitochondria.

1.1.1 Mitobiogenesis signaling
Mitochondria are unique organelles in that they have their own genome. The
double-stranded, circular mammalian mitochondrial genome encodes 13 proteins that
are essential for respiratory chain function and oxidative phosphorylation, 2 rRNAs and
22 tRNAs [6, 7]. Mitochondria are not self-sufficient, however, and rely on the nuclear
genome to encode most of the ~1200-1500 proteins they require. Mitochondrial DNA
(mtDNA) is particularly susceptible to damage by ROS because it has no histones, it is
physically close to the respiratory chain where most ROS are generated, and
mitochondria have only limited enzymes for repair of oxidatively damaged DNA.
Deletions in mtDNA may arise from aberrant repair of oxidatively damaged mtDNA,
have been found in tissues including the brain, skeletal muscle, and heart, and
accumulate with age [8]. Low levels of these deletions would not be immediately
harmful because cells have thousands of copies of mtDNA. However, with age or
disease, mutations and deletions can accumulate [9, 10] and lead to decreased
mitochondrial respiration and ATP production. Most mtDNA deletions and mutations are
heteroplasmic, meaning the cell has a mixture of normal and mutated mitochondrial
DNA, but mutations can be homoplasmic as well [11].
As depicted in Figure 1, mitobiogenesis is the process by which cells increase
their mitochondrial components, which includes transcription of genes encoded by both
the mitochondrial and nuclear genomes. Peroxisome proliferator-activated receptor

2

gamma, co-activator 1-α (PGC-1α) is an upstream regulator of transcription factors
involved in mitobiogenesis and respiration including nuclear respiratory factors 1 and 2
(NRF1, NRF2) and mitochondrial transcription factor A (TFAM) [12, 13]. For this reason
PGC-1α is thought to be the ‘master regulator’ of mitobiogenesis. PGC-1α is regulated
by chromatin remodeling [14, 15] as well as posttranslational modification [16]. PCG-1α
interacts directly with NRF1 and 2 and estrogen-related receptor α (ERRα) which then
translocate to the nucleus [17-19]. This results in an increased transcription of genes
including those encoding ETC subunits and TFAM, which are then localized to the
mitochondria [20]. TFAM is required for mtDNA maintenance and stimulates its
bidirectional transcription [21]. A mitochondrial DNA-directed RNA polymerase
(POLRMT) and mitochondrial DNA polymerase gamma (POLG) then perform mtDNA
transcription and replication, respectively [22].
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Figure 1. Mitobiogenesis signaling. PGC-1α binds to NRF1/2 and ERRα,
initiating gene expression of mitochondrial components
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1.1.2 Mitobiogenesis in ALS
Mitochondrial dysfunction has been well characterized in a number of
neurodegenerative diseases including Parkinson’s disease, Alzheimer’s disease, and
ALS. ALS is characterized by loss of both upper motor neurons in the cerebral cortex
and lower motor neurons in the brainstem and spinal cord. Death of lower motor
neurons leads to progressive muscle weakness and atrophy with respiratory failure
being the leading cause of death an average of three to five years after diagnosis [23,
24]. ALS presents in late adulthood, is more common in men than women, and affects
2-5 per 100,000 people worldwide [25]. Over 90% of cases have no family history of the
disease, which thus occurs sporadically in most (sALS).
Mitobiogenesis appears to be impaired in post mortem tissues of patients with
sALS. PGC-1α and its downstream targets showed decreased expression in post
mortem spinal cord and muscle from sALS patients [5]. Additionally, there was
decreased activity of ETC subunits and increased mtDNA deletions in isolated post
mortem spinal motor neurons [1-3] and skeletal muscle [4] of sALS patients.
Mitochondrial encoded gene expression was significantly depressed in peripheral blood
mononuclear cells (PBMCs) of sALS patients compared to neurologically healthy
controls [26]. This suggests a systemic bioenergetic impairment. Interestingly, healthy
human oculomotor neurons isolated from post mortem tissue showed increased gene
expression related to mitochondrial function when compared to spinal motor neurons
[27]. Upregulation of mitobiogenesis could be a protective mechanism and may be one
reason why oculomotor neurons and PBMCs are spared in ALS.
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The most widely studied form of ALS is the inherited form of the disease, familial
ALS (fALS), which composes only 5-10% of all cases. The first genetic mutation
associated with ALS was found in the enzyme Cu, Zn superoxide dismutase 1 (SOD1)
and occurs in approximately 20% of fALS patients, less than 2% of total cases. Even
less common genetic mutations known to cause ALS are in the RNA-binding proteins
TAR DNA-binding protein 43 (TDP43) and fused in sarcoma (FUS), among many
others. Recently, hexanucleotide repeats in the non-coding region of the C9ORF72
gene was found to be responsible for approximately 22% of fALS cases and is present
in 4% of sALS cases [28].
A murine model has been created that expresses human mutant SOD1 at supraphysiological levels. This model replicates some components of the disease, however it
does not fully mimic the human disease condition. Much of our understanding of the
mechanisms of ALS comes from studies using these mice, however translation of drugs
and therapies identified by this model into patients has been disappointing. The only
FDA approved treatment for ALS is riluzole; however, it was shown to only increase
patient survival by two to three months and does not reverse progression of the disease
[29].

1.2 Differentiation of motor neurons in vivo
There are unique signaling cascades during development that define the identity
of every type of cell in the body. In order to make motor neurons in vitro we need to
understand what normally happens during human development in vivo.
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1.2.1 Signaling during development
Spinal motor neurons are some of the most well characterized cell types in terms
of their embryonic origin. Early in development the inner cell mass of the blastocyst
specifies into the three germ layers: endoderm, ectoderm, and mesoderm. The
patterning of the nervous system is due to repressing and activating signals from a
multitude of transcription factors and other proteins [30]. This process is summarized in
Figure 2, adapted from [31]. The dorsal portion of the ectoderm becomes the nervous
system through inhibition of bone morphogenic proteins (BMPs) and activin signaling
[32, 33]. After formation of the neural tube the hindbrain and spinal cord is specified
from the forebrain and midbrain along the rostro-caudal axis by retinoic acid [34] (RA;
Figure 2A). Following this, dorsoventral signaling specifies cell types [35] (Figure 2B).
Motor neurons derive from the ventral portion of the neural tube and receive a high
concentration of sonic hedgehog (SHH) signaling from the notochord and floor plate
(FP). Opposing SHH is a concentration of BMP/TGFβ signaling from the roof plate. Also
during this time RA is continuing to be released from somites [34]. These signaling
gradients produce a grid-like order to the 5 progenitor domains of the spinal cord, V0-V3
interneurons and motor neurons (Figure 2B). SHH signaling activates homeodomain
domain protein Nkx6.1, which induces transcription of MNR2, among others [30, 36].
MNR2 is a transcription factor is critical to the differentiation of motor neurons [36].
Following its expression cells exit the cell cycle and express Islet 1 and 2 (Isl1, Isl2) and
the motor neuron specific transcription factor HB9 [30].
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Figure 2. Motor neuron specification in the developing embryo A)
Motor neurons derive from the dorsal ectoderm in response to inhibition of
BMP and activin signaling and retinoic acid B) BMP signaling from the roof
plate (RP) opposes sonic hedgehog (SHH) signaling from the notochord
(NC) and floor plate (FP). Retinoic acid (RA) is released from the somites
(S).
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1.2.2 Electrical properties of embryonic spinal motor neurons
As motor neurons differentiate there is a dramatic change in passive membrane
properties as well as an increase in soma size and neurite complexity. Passive
membrane properties including input resistance and membrane time constant decrease
during postnatal development of rat motor neurons [37]. Resting membrane potential
becomes more hyperpolarized during late embryonic development of rat motor neurons
[38] but then remains unchanged from neonatal to adult cells [37]. Membrane
capacitance (Cm), an indicator of cell surface area, is increased during embryonic
development of rat spinal motor neurons [39]. Many of these findings are replicated in
motor neurons differentiated from human embryonic stem cells (hESCs). Input
resistance, but not resting membrane potential, decreased [40] and soma size and
complexity of neurite outgrowth increased during hESC-derived motor neuron
maturation [40].
Voltage-gated ion channels are critical to proper motor neuron function. The
major currents that underlie motor neuron resting membrane potential and action
potential are sodium, potassium, and calcium currents. These currents are present at a
very early stage in development and undergo changes during motor neuron maturation.
All four voltage gated sodium channel subunits expressed in the central nervous
system are also expressed in embryonic rat motor neurons, Nav1.1, 1.2, 1.3, and 1.6
[41]. Previous studies in multiple animal models have identified that the upswing of the
motor neuron action potential is underlay by the fast inactivating sodium current. The
action potential is kept short by the fast inactivation of these channels and the necessity
to return to the resting membrane potential before reactivation allows for a refractory
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period in which another action potentials cannot be initiated. In this way recovery from
inactivation of voltage gated sodium channels can control action potential firing
frequency. Detailed activation and inactivation kinetics are difficult to study in motor
neurons using voltage-clamp techniques. Due to their large size, the membrane takes
more time to charge and extensive dendritic processes make it difficult to control the
voltage of the cell (space clamp).
Potassium currents play important roles in motor neuron resting membrane
potential, action potential shape, and firing behavior. Both transient (IA) and delayed
rectifier (IK) potassium currents are seen in motor neurons in vivo [42] as well as in
hESC-derived motor neurons [40]. These currents are responsible for the rapid
repolarization of the membrane during an action potential. Potassium channels also
underlie the afterhyperpolarization (AHP), a period of membrane hyperpolarization that
occurs after an action potential is generated. The AHP can be broken down into fast,
medium, and slow components. Large conductance (BK) and small conductance (SK)
calcium-activated potassium channels underlie the fast and medium components of the
AHP, respectively. It is unknown what channels underlie the slow AHP, but previous
studies implicate potassium channels in the KCNQ family [43].
In isolated chick motor neurons there were slightly more sodium currents than
potassium currents (~70 pA/pF compared to ~60 pA/pF)[44]. From E4-E11 sodium
current density increased 60% and correlated with increased action potential amplitude.
During this time there was a large increase (16 fold) in IA and a small (25%) increase in
IK. The increase in IA resulted in a shortening of action potential duration with motor
neuron maturation[44]. Calcium currents matured last, with L- and N- type currents
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increasing slightly during E4-11 and T-type currents decreasing[45]. Calcium currents
were very small compared to sodium currents, and the fact that TTX blocked action
potential generation suggests that action potential generation is sodium channel
dependent during this time period.

1.3 Intrinsic susceptibility of motor neurons
Alpha (α)-motor neurons are selectively vulnerable in ALS, with fast fatigable
(FF) motor units degenerating faster than slow (S) motor units [46]. Interestingly, there
are two populations of motor neurons that are spared in the disease. Motor neurons in
Onuf’s nucleus in the sacral section of the spinal cord that control voluntary bladder and
rectal sphincters, and oculomotor nuclei in the brainstem that control voluntary eye
movements are spared in both sporadic and genetic forms of ALS [27]. It is unknown
why only specific cell types, even within the motor neuron population, are lost in this
disease. However, by looking at the properties that distinguish these cells from other
cell types may give us insights into why they are more vulnerable.

1.3.1 Calcium buffering
Control of motor neuron excitability is vital to optimal development of sustained
muscle contractions [47]. Calcium is a second messenger in many signaling cascades
and plays an important role in the repetitive firing properties of motor neurons. An
increase in calcium depolarizes the cell and makes it more likely to fire action
potential(s). However, increased intracellular calcium could lead to greater reliance on
mitochondria to buffer calcium and therefore exacerbate mitochondrial damage caused
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by normal aging. Combined with a genetic susceptibility to ALS and/or environmental
factors this could lead to ALS pathology.
Motor neurons are predicted to have problems handling large amounts of calcium
because of their low content of calcium buffering molecules such as calbindin-D2sK and
parvalbumin [48], and their large size [49]. For this reason, they rely on intracellular
organelles like mitochondria to take up excess calcium. Previous studies using rat and
mouse spinal motor neurons in vitro revealed an increased reliance on mitochondria to
buffer calcium as compared to other neuron types [50, 51]. In brainstem slices from
mice mitochondrial dysfunction induced by blocking complex IV of the ETC or
uncoupling ATP synthesis resulted in increased intracellular calcium and excitability of
motor neurons [52]. Because mitochondria accumulate cytosolic calcium mainly in a
membrane potential (ΔψM)-dependent manner through the calcium uniporter,
bioenergetic impairments and/or excessive “leak” of protons across a damaged inner
membrane are predicted to lower ΔψM and reduce mitochondrial calcium buffering.
Unfortunately, mitochondria show a decline in bioenergetic function with age and
disease. Therefore, aging itself may contribute to motor neuron death due to a reduced
capacity for calcium buffering leading to calcium-mediated activation of cell death
signaling.
Motor neurons also have a large number of calcium permeable glutamate
receptors. Glutamate is an excitatory neurotransmitter and an increase in glutamate
leads to an influx of sodium and calcium into the cell. One type of ionotrophic glutamate
receptors is the α-amino-3-hydroxyl-5-methyl-4-isoxazole-propionate (AMPA) receptor.
Normally pre-mRNA for the GluA2 subunit of the AMPA receptor is edited by adenosine

12

deaminase acting on RNA 2 (ADAR2) at a specific site, converting adenosine to
inosine. During translation, this site is read as an arginine (R) instead of a glutamine
(Q). AMPA receptors containing the edited GluA2 subunit conduct mainly sodium;
however the lack of this subunit or improper editing allows the channel to conduct
calcium as well. Human spinal motor neurons contain a large number of calcium
permeable AMPA receptors that lack the GluA2 subunit when compared to other neuron
types [53, 54]. Additionally, human oculomotor neurons showed increased expression of
the GluR2 subunit compared to spinal motor neurons [27]. Additionally, increased
glutamate has been found in the cerebral spinal fluid of sALS patients [55]. This may be
explained by loss of the glial glutamate transporter EAAT2 in spinal cord and motor
cortex of sALS post mortem tissue [56]. EAAT2, predominately expressed in astrocytes,
allows for the uptake of excess glutamate in the extracellular space.
Motor neurons are also unique in their expression of voltage gated calcium
channels. They express both high-voltage-activated and low-voltage-activated calcium
channels that play a role in action potential duration [42]. High-voltage-activated L-type
channels, specifically subtype Cav1.3, have been shown to mediate the persistent
inward current (PIC) that underlies plateau potentials in spinal motor neurons [57, 58].
Cav1.3 channels open at approximately -55 mV, near the resting membrane potential
and 20 mV below the other L-type calcium channel expressed in the mammalian
nervous system, Cav1.2 [59]. This allows calcium influx even at rest or with small
depolarizations. In mice there is low expression of Cav1.3 in spinal motor neurons at
birth but expression increases as motor neurons mature, reaching adult levels by
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postnatal day 18 [57, 60]. The expression of Cav1.3 channels in human motor neurons
has not been studied.

1.3.2 Plateau potentials
Another property of motor neurons is the ability to generate plateau potentials.
Plateau potentials are characterized by sustained membrane depolarizations after a
stimulus has been terminated. Plateau potentials are activated by excitatory synaptic
input or membrane depolarization, which then activates PICs of calcium and sodium.
PICs act to amplify incoming signals [61-63]. The sodium PIC is activated quickly but
quickly inactivates, and plays an important role in initiating action potentials during
repetitive firing [61, 62, 64]. The calcium PIC activates slowly but is persistent and
increases in amplitude with repeated excitatory stimulation [62, 65].

1.3.3 Repetitive firing
Increased intracellular sodium and calcium and/or a decreased potassium results
in a cell that is more likely to fire action potentials. The generation of repetitive action
potential firing in response to a sustained stimulus is a characteristic of mature motor
neurons. Repetitive firing is modulated by the afterhyperpolarization (AHP). AHP is a
period of hyperpolarization after an action potential is fired in which the neuron’s
membrane potential is lower than normal, inhibiting further action potentials. The AHP
can be broken down into fast, medium and slow components (fAHP, mAHP, and sAHP).
It is unknown exactly which channels underlie the sAHP, but voltage-gated potassium
channels in the KCNQ family have been implicated. Large (BK) and small conductance
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calcium-activated potassium (SK) channels underlie the fAHP and mAHP, respectively.
When these channels are opened by calcium binding, they allow the efflux of
potassium, repolarizing the cell. An increase in SK channel conductance would result in
fewer action potentials, while a decrease would result in repetitive firing of action
potentials. Motor neurons rely heavily on these channels to mediate the proper balance
of repetitive firing.
Lengthening the AHP after an action potential is fired, by activating SK channels,
may be beneficial to hyperexcitable motor neurons in sALS patients. Additionally, SK
channel activation would result in decreased intracellular calcium through negative
feedback on NMDA receptors. When glutamate binds NMDA receptors there is no influx
of calcium until there is membrane depolarization, relieving a magnesium block of the
channel. When this happens, an increase in intracellular calcium activates SK channels,
potassium effluxes, and the membrane repolarizes. Riluzole, the only FDA-approved
treatment for ALS, decreases the excitable neurotransmitters glutamate and sodium in
the synapse [66]. A recent study suggests that riluzole activates SK channels as well
[67]. The fact that riluzole has many targets may explain why it is not more effective in
treating ALS. If we were able to determine which mechanism(s) of action were most
beneficial for motor neuron survival, we may be able to develop improved drugs that
have less unintended activity.
Another current that underlies bursts of action potentials is the hyperpolarizationactivated current (Ih). Channels that underlie Ih are permeable to both sodium and
potassium and Ih acts to return the membrane back to resting after being hyperpolarized
[37]. Ih increases with postnatal maturation and underlies rebound depolarizations. This

15

current may play a role in rebound bursts of action potential firing seen after inhibitory
synaptic input in both native and hESC-derived motor neurons [40, 42].

1.3.4 Properties altered in ALS
Hyperexcitability has been seen in ALS patients [68-70] and in a mouse model of
ALS [71, 72]. In mice, hyperexcitability is one of the earliest phenotypes, occurring long
before symptom onset, and appears to be due to active rather than passive membrane
properties. There was no change in the resting membrane potential, input resistance,
action potential duration, amplitude, or threshold, or in afterhyperpolarization between
mice carrying a G93A mutation in SOD1 and controls [71, 72]. There was, however, a
significant increase in action potential firing frequency and the amount of current
necessary to fire an action potential (rheobase) in the mutant mice [71-73]. This
increase in excitability could be due to a number of factors, including increased inward
and/or decreased outward currents.
In ALS patients there is evidence for an imbalance of sodium and potassium
channels [74, 75]. Increased sodium conductance was seen in motor neurons from
fALS patients. In contrast, one study found a decrease in the voltage gated potassium
channel Kv1.2 was found in the ventral roots of sALS patients but no change in sodium
channels [76]. Alteration in sodium and potassium currents is also seen in the SOD1
mouse model. Motor neurons from SOD1 mutant mice show increases in both sodium
and calcium PICs and develop mature action potentials faster than their wild-type
counterparts [66]. Isolated embryonic motor neurons from SOD1 mutant mice show
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increased recovery from fast inactivation of voltage gated sodium channels when
compared to mice expressing normal human SOD1 and wild type mice [77]. This could
decrease the refractory period after an action potential is fired, leading to an increase in
firing rates.

1.4 hPSCs
The classification of human pluripotent stem cells (hPSCs) includes both human
embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs). hESCs are
derived from the inner cell mass of a pre-implantation blastocyst [78]. These cells can
divide indefinitely while remaining pluripotent, or can be differentiated into any cell type
in the body. Initially there was much hope for hESCs in disease modeling and cell
replacement therapies. However, ethical issues and transplantation rejection concerns
have limited their use in humans. iPSCs, on the other hand, could be derived from the
patients’ own cells and therefore have the same genetic background. This would be
particularly important for modeling complex diseases like ALS in which there is no one
gene mutation that causes the disease. If motor neurons derived from ALS patient
iPSCs replicate features seen in the disease they may be useful for understanding ALS
pathology and testing therapies.

1.4.1 Reprogramming of somatic cells
Initial reprogramming studies found that somatic cells could be reprogrammed
into pluripotent cells by nuclear transfer into oocytes [79] or by fusion with ESCs [80,
81]. This suggests that there are soluble factors that determine pluripotency. In 2006
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retroviral transduction of four transcription factors, Oct3/4, Sox2, c-Myc, and Klf4, was
sufficient to induce reprogramming of mouse fibroblasts [82]. The next year the same
was found for human fibroblasts [83]. Since then other cells have been reprogrammed
including blood cells [84, 85].
Although integration of foreign DNA is efficient at reprogramming somatic cells,
these types of cells would not be safe for clinical use because of their potential for DNA
mutations. To address this issue many protocols have been developed to deliver
recombinant proteins or mRNA. However, the efficiency of reprogramming using these
methods is extremely low and the proteins must be delivered multiple times for a period
of several weeks. Another option is to express the reprogramming factors using a nonintegrating plasmid. The latent origin of plasmid replication (oriP) and one viral protein,
Epstein-Barr Nuclear Antigen 1 (EBNA1) from the Epstein-Barr virus has been shown to
be sufficient for replication of the viral plasmid [86] and adding these elements to a
plasmid containing four reprogramming factors allows their expression without DNA
integration. Expression of the Simian virus 40 (SV40) large T antigen allows for
enhanced reprogramming efficiency and the foreign DNA is spontaneously lost after 1012 passages [87-89]. It is unknown exactly how expression of the SV40 T antigen
increases reprogramming efficiency, however it may act to increase transcription
replication of the plasmid. This plasmid system has been used to reprogram human
peripheral blood mononuclear cells (PBMCs) with a single transfection in as little as 14
days and the epigenetic profile of iPSCs derived from PBMCs shows promoter DNA
methylation status more similar to human ES cells than iPSCs derived from fibroblasts
[89]. In 2012 a protocol was described that increases the efficiency of PBMC
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reprogramming with an improved EBNA1/OriP-based plasmid expressing five
reprogramming factors (Oct4, Sox2, Klf4, c-Myc, and Lin28) as a single unit separated
by 2A peptide sequences which allows for the co-translational cleavage into individual
peptides [90]. PBMCs isolated from as little as five milliliters of peripheral blood can be
used fresh or after freezing and lymphocytes are eliminated before reprogramming to
reduce the chance of somatic recombination found in T lymphocytes [90]. In addition to
having a favorable epigenetic profile after reprogramming, PBMCs are less invasive to
obtain than fibroblasts, and are exposed to fewer environmental mutagens. Also,
PBMCs need less time in culture before reprogramming and generate colonies faster
after reprogramming than fibroblasts [89].

1.4.2 Using iPSCs to study ALS
The reprogramming of fibroblasts from patients with fALS with a mutation in
SOD1 into iPSC and subsequent motor neuron differentiation was first reported in 2008
[91]. Since then many types of fALS have been modeled using iPSCs from patient
fibroblasts including TDP43 [92, 93], C9ORF72 [94, 95], and vamp-associated protein
B/C (VAPB)[96]. Only one study to date has used iPSCs from sALS patients [97]. All of
these studies describe the chemical characteristics of iPSC derived motor neurons,
including immunostaining for the motor neuron transcription factors HB9 and Islet1,
followed by expression of choline acetyltransferase (ChAT). Many also show functional
characterization of ion channel and action potential formation by whole cell patch clamp.
There are data to suggest that these cells retain disease-causing mutations
during reprogramming and display a phenotype similar to what is seen in patients.
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Motor neurons differentiated from patient iPSCs with mutations in TDP43 conserved
genetic mutations and increased vulnerability to cell stress [92, 93].
Recent findings suggest that iPSCs from fALS patients show some of the same
characteristics of intrinsic hyperexcitability seen in the disease. ALS iPSC-derived motor
neurons with mutations in three different genes displayed increased spontaneous firing
when compared to healthy or isogenic controls [98]. Upon further investigation the
authors found decreased magnitude of delayed-rectifier potassium currents but no
change in sodium currents. Treatment with retigabine, an activator of delayed-rectifier
potassium channels, decreased spontaneous firing and increased survival of ALS
patient derived motor neurons [98].
Another study found that motor neurons derived from ALS patients with a
hexanucleotide repeat in C9ORF72 are more susceptible to glutamate toxicity. This
could be rescued by antisense oligonucleotides targeting C9ORF72 or by knockdown of
an RNA binding protein, ADARB2. ADAR proteins mediate editing of the GluR2 AMPA
receptor, making it calcium impermeable. Without this editing, as happens in sALS [99],
AMPA receptors are calcium permeable and may contribute to excitotoxicity [95].
1.4.3 Mitochondrial regulation in hPSCs
Respiration analysis suggests that hPSCs produce the majority of ATP through
anaerobic glycolysis compared to mitochondrial oxidative phosphorylation (OXPHOS) in
somatic cells [100-103]. The details of this reversible switch remain unclear, and may
vary between different cell lineages. Initial studies reported that hPSCs had few,
underdeveloped mitochondria [104-106]. Recent studies have shown that while they
rely on glycolysis for ATP production, hPSCs have active respiratory chain complexes
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and respire at maximal capacity [100, 107]. Glycolysis is not as efficient at making
energy but is faster and produces less ROS than OXPHOS. The switch to OXPHOS
during differentiation would require increased mitochondrial respiratory capacity. There
is evidence to suggest that this is achieved by an increase in mitochondrial mass, ATP
and subsequent ROS production during spontaneous differentiation of hPSCs [108,
109]. This process is reversed during reprogramming of somatic cells into iPSCs.
Recent studies have started to shed light on the mechanisms underlying the
switch from glycolysis to OXPHOS during cellular differentiation. One protein thought to
be involved in this switch is uncoupling protein 2 (UCP2). UCP2 is a mitochondrial
protein located in the inner membrane and is thought to uncouple the ETC from the
production of ATP by allowing protons to leak through the membrane. The exact
function of UCP2 remains unknown but recent findings implicate it in the metabolic
change from glycolysis to OXPHOS during cellular differentiation by decreasing glucose
utilization by mitochondria [110, 111]. UCP2 expression decreased during neuronal
differentiation of mouse embryonic stem cells [112]. Hypoxia-inducible factor one alpha
(HIF1α) is another protein that appears to be important for iPSC reprogramming. A
recent study found increased HIF1α in undifferentiated cells and activation of HIF1α
resulted in increased glycolysis and improved reprogramming [113].

1.4.4 Low oxygen conditions
Normal cell culture conditions grow cells in room air containing approximately
20% oxygen. This is much higher than what cells are exposed to in the developing or
adult nervous system. Interstitial tissue oxygen levels in the mammalian brain range

21

from ~1-5% [114]. Low oxygen conditions (2-5%) have been shown to enhance
proliferation, differentiation and survival of stem cells and neurons [115-118], including
spinal motor neurons [117]. No ALS iPSC studies to date have used low oxygen
conditions.

1.5 Aims of the study
The hypothesis to be tested in the current study states that differentiation of
human pluripotent stem cells into electrically excitable motor neurons will result in
increased mitochondrial biogenesis.

The specific aims are:
1. To generate motor neurons from hESC- and iPSC-derived human neural stem
cells
2. To determine the effect of motor neuron differentiation on mitobiogenesis in
human neural stem cells in 5% oxygen conditions
3. To examine the electrophysiological maturation of hPSC-derived motor neurons
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CHAPTER TWO
GENERAL METHODS

2.1 Culture of hESC-derived hNSCs
GIBCO® Human Neural Stem Cells were purchased from Life Technologies
(Grand Island, NY). These cells are derived from the NIH approved human embryonic
stem cell line H9 (WA09) and retain a normal human female karyotype for multiple
passages. They can be differentiated into neurons, oligodendrocytes, or astrocytes. To
remain in an undifferentiated state cells were grown in KnockOut D-MEM/F-12
containing 2 mM GlutaMAX-I supplement, 20 ng/mL human recombinant basic
fibroblast growth factor (bFGF) and epidermal growth factor (EGF) and 2% StemPro
neural supplement up to passage 32. Medium was changed every 2-3 days and cells
were maintained between 50 and 90% confluence. When cells were ~90% confluent
they were dissociated using TrypLE™ and plated on culture vessels coated with
CELLStart™. All cultures were grown at 37°C in 5% oxygen and 5% CO2 conditions.

2.2 iPSC generation and neural induction
Peripheral blood was collected from one healthy male control patient, age 62, in
accordance with a Virginia Commonwealth University IRB-approved protocol at the
Parkinson’s and Movements Disorder’s Center. Integration-free iPSCs were generated
from human peripheral blood mononuclear cells (PBMCs) using a previously described
protocol[90], with modifications. Specifically, blood was collected in sodium citrate
vacutainers and PBMCs were isolated using Ficoll-Paque Premium (GE Healthcare)
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density gradient centrifugation within 4 hours of draw time. PBMCs were expanded by
culturing for two weeks in PBMC medium that supports erythroblast expansion and
eliminates lymphocytes. Lymphocytes were not used for reprogramming because of
their high incidence of somatic rearrangements. The pEB-C5 and pEB-Tg plasmids
were obtained from Addgene (Cambridge, MA) and grown in the VCU Macromolecular
Core Lab. The pEB-C5 plasmid contains five reprogramming factors (OCT4, SOX2,
KLF4, c-MYC, and Lin28) and the pEB-Tg plasmid contains the SV40 large T antigen
that enhances reprogramming efficiency. 3x106 PBMC were electroporated with the
plasmids using an Amaxa Nucleofector 4D (Lonza, Allendale, NJ). This technique uses
electrical pulses to permeabilize the cell membrane in order to allow the plasmid access
to the cytosol. Immediately following electroporation an equal volume of 37 °C RPMI
medium was added to the cuvette and the cells allowed to recover for 10 min at 37 °C
before returning to culture in PBMC medium. Transfected cells were co-cultured on
mouse embryonic fibroblasts beginning at day 2 and the schedule of medium changes
outlined in the protocol were followed. On day 14 maintenance medium was changed
to mTeSr (Stem Cell Technologies, Vancouver, BC) and colonies with PSC morphology
were picked to wells of a 96 well plate beginning at about day 21. Viable colonies were
expanded in mTeSR medium on Geltrex (Life Technologies, Grand Island, NY) coated
plates at 37° C in a humidified CO2 incubator with the oxygen level held at 5%. Growth
medium supplemented with 10 uM ROCK inhibitor Y27632 (R&D Systems, Minneapolis,
MN) was used for the first 24 hours after colonies were split.
Neuralization of iPSCs was accomplished using PSC Neural Induction Medium
(Life Technologies) according to protocol [119] with modifications. This protocol allowed
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for a faster, less labor-intensive, and consistent neural induction protocol. Briefly, iPSC
colonies were maintained in PSC Neural Induction Medium beginning at day 1 after
splitting. On day 5 colonies with good morphology were picked to fresh Geltrex coated
dishes and induction continued for another 5 days. On day 10 colonies were detached
using Accutase (Life Technologies), passed through a 100 um strainer, centrifuged at
300 x g for 4 min. and plated in neural expansion medium on Geltrex coated dishes.
Cultures were maintained at 37° C in a humidified CO2 incubator with the oxygen level
held at 5%. Growth medium supplemented with 10 uM ROCK inhibitor Y27632 (R&D
Systems, Minneapolis, MN) was used for the first 24 hours after the neural stem cells
were split through passage 4.

2.3 Differentiation of hNSCs into motor neurons
For differentiation of hESC-derived hNSCs into motor neurons media was
changed to neurobasal medium containing 2% B-27 serum-free supplement and 2 mM
GlutaMAX-I supplement plus 0.1 µM retinoic acid (RA) for 7 days followed by 7-21 days
of 0.1 µM RA plus 0.5 µM purmorphamine (PM) [117, 120-126]. Media was changed
every 2-3 days and cultures received half media changes except on days 0 and 7, when
cultures received full media changes. RA and PM concentrations and timing were
chosen based on previous studies [120, 127].
After neural induction, iPSCs were differentiated as described previously, with
some modifications [128]. Briefly, adherent cells were grown in neural induction media
containing DMEM/F12 with 0.2 µM LDN-193189 (LDN; Stemgent), 10 µM SB431542
(SB; Stemgent), 10 ng/ml BDNF (R&D systems), 0.4 ug/ml L-ascorbic acid (Sigma), 2
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mM GlutaMAX-I supplement, 1% N-2 supplement, and 1% nonessential amino acids
(NEAA). Two days later 1 µM RA was added. On day four LDN/SB was stopped and 1
µM smoothened agonist (SAG; Calbiochem or Santa Cruz) and 0.5 µM PM were added.
On day 14 cells were switched to neurobasal media containing 2 mM GlutaMAX-I, 2%
B-27, 1% NEAA, 0.4 ug/ml AA, 10 ng/ml GDNF (R&D), 10 ng/ml CNTF (R&D). Media
was replaced every 2-3 days. Unless otherwise specified, all cell culture materials were
purchased from Life Technologies. All cultures were grown at 37°C in 5% oxygen and
5% CO2 conditions.

2.4 Nucleic acid isolation and cDNA synthesis
For qPCR analysis of hESC-derived cells DNA and RNA were extracted at
seven-day time points through day 28 using the AllPrep DNA/RNA Mini Kit (Qiagen)
according to manufacturer instructions. In order to achieve increased yield and quality,
for iPSC-derived cells RNA was extracted at D0 and D21 with the RNeasy or RNeasy
Plus Micro Kit (Qiagen) and DNA was extracted with the DNeasy Blood and Tissue Kit
(Qiagen) according to manufacturer instructions. Quantification of isolated DNA and
RNA was performed using a Nanodrop 2000c spectrophotometer (Thermo Scientific).
RNA was reverse transcribed into cDNA using the iScript or iScript Advanced cDNA
synthesis kit (BioRad) which uses both random hexamer and oligo dT primers, following
the manufacturer’s protocol.
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2.5 Quantitative PCR
For qPCR, 25-50 ng cDNA or 0.1 ng of DNA per well was loaded into a 96-well
plate and analyzed with the CFX-96 Real-Time PCR Detection System (BioRad) using
relative quantitation methods. All samples were analyzed in triplicate. Neuronal markers
(NEFL, MAP2, and TUBB3), TFMB2, and mtDNA-encoded genes (12s rRNA, ND2,
CO3, ND4) were measured using a multiplex qPCR assay. Endogenous reference
genes (TOPO1, 14-3-3-Z, GAPDH, B2M, CYC1, AND UBC), pluripotency genes (KLF4,
CMYC, LIN28, OCT4, SOX2) mitochondrial biogenesis genes (PGC-1α, POLG,
POLRMT, TFAM, ERRα, NRF1, NRF2), glial markers (GL1-1 and GFAP), NSE was
measured individually using EvaGreen PCR. Primers for PGC-1α were specifically
designed in a region to detect all major isoforms. Primer sequences can be found in
Figure 3. Reagents included SsoFast EvaGreen® Supermix (BioRad) and primers
designed with Beacon Designer software (Premier Biosoft international, Palo Alto, CA)
and supplied by Eurofins MW Operon (Huntsville, AL). PCR conditions were 30 seconds
at 95 °C, followed by 40-45 cycles of 10 seconds at 95 °C and then 15 seconds at Tm
(primers) -5 °C. Melt curve analysis was used to verify primer specificity, and efficiency
was determined using standard curve analysis of commercially available human fetal
brain total RNA (Clontech, Mountain View, CA).
All gene expression analysis were conducted using the qbasePLUS® relative
quantitation method (Biogazelle qbasePLUS®, http://www.biogazelle.com), which is a
modification of the ΔΔCq method that allows normalization with multiple reference
genes. Data was normalized to the geometric mean of two reference genes determined
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to have the greatest stability using the software qbasePLUS-GeNorm (BioGazelle;
14.3.3.Z and CYC1 for cDNA and CYC1 and GAPDH for gDNA for both cell types).

ND2
ND2
ND2

PROBE
SP
ASP

MtDNA encoded genes
[6-FAM]CACGCAAGCAACCGCATCCATAAT[BHQ1a-Q]
AAGCTGCCATCAAGTATTTCC
GTAGTATTGGTTATGGTTCATTGTC

COX3
COX3
COX3

PROBE
SP
ASP

[5TET]CGAAGCCGCCGCCTGATACTG[BHQ1a-Q]
TTTCACTTTACATCCAAACATCAC
CAATAGATGGAGACATACAGAAATAG

ND4
ND4

PROBE
SP
ASP

[AminoC6+TxRed]AGCCAGAACGCCTGAACGCAG[BHQ2aQ]
TGGCTATCATCACCCGATG
GGTGTTGTGAGTGTAAATTAGTC

12SrRNA
12SrRNA
12SrRNA

PROBE
SP
ASP

[Cy5]CGCCAGAACACTACGAGCCACAG[BHQ3a-Q]
CCTCAACAGTTAAATCAACAAAAC
CTGAGCAAGAGGTGGTGAC

POLg

SP
ASP

Mitobiogenesis genes
TGGTCAAACCCATTTCACTG
AGAACACCTGGCTTTGGG

ERRa

SP
ASP

CTTCGCTCCTCCTCTCATC
CTGGAGTCTGCTTGGAGTTAT

NRF1

SP
ASP

TTTGTATGCCTTTGAAGAT
AACCTGGATAAGTGAGAC

NRF2

SP
ASP

GTTACAACTAGATGAAGAGACA
ATCCACTGGTTTCTGACT

TFAM

SP
ASP

AATCTGTCTGACTCTGAA
CACATCTCAATCTTCTACTT

TFMB2

SP
ASP
Probe

GTATCTTATTCAAATGATTCCTC
TAAGTGGTCTATTACAGTGG
[5TET]ACCAAGA...AACT[BHQ1a-Q]

ND4
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PGC1a

SP
ASP

GATGTGAACGACTTGGAT
TTGAAGGCTCATTGTTGTA

POLRMT

SP
ASP

AAGATACTGGAGAAGGATAAGC
GCTCTGGAATGGCATCTG

Isl1

SP
ASP

GTTGGAGAAAGTGGGAAAT
CTACCATATCACCTTGTCATT

VACht

SP
ASP

ACTCCTCAACCTTGACTTC
CCATTGGACAAGAGAGAAAG

HB9

SP
ASP

GTGAGAAGAACCGACCCACC
CTCCAGAGGCGGTTTCAAGT

TOPO1

SP
ASP

Reference genes
TGAGCCAGATAACAAGAA
TTGATGCCTTCAGGATAG

14-3-3-Z

SP
ASP

GTAGACCATTTGTCATCCAT
AGAAGTAACATAAACCTGTCATA

CYC1

SP
ASP

ACTGCGGGAAGGTCTCTA
TGCCATCGTCAAACTCTAAG

B2M

SP
ASP

TATCCAACATCAACATCT
TTCCAATAATCCTGTCAA

UBC

SP
ASP

ATTTTAGGACGGGACTTG
CGAGAAGGGACTACTTTT

GAPDH

SP
ASP

GTCGGAGTCAACGGATTT
CAACAATATCCACTTTACCAGAG

KLF4

SP
ASP

Pluripotency genes
CCTTGCTGATTGTCTATT
AAGTCAACGAAGAGAAGA

CMYC

SP
ASP

CGCATCCACGAAACTTTG
CTTGCTCGGGTGTTGTAA

LIN28

SP
ASP

CCAGAGTGAAATGATTAAGTA
GAGGATACAAGATGTGAAAA
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OCT4

SP
ASP

AGGAAGCTGACAACAATG
TGGTTCGCTTTCTCTTTC

SOX2

SP
ASP

ATGGTTGTCTATTAACTTGT
TCTCTCCTCTTCTTTCTC

NEFL

SP
PROBE
ASP

Neuronal genes
CTCCCGAAATCAGGTCAA
[5-FAM]CCATCACCAACCAACCAACCAG[BHQ1a-Q]
GAGGAAATTCATAGCACAACA

MAP2

SP
PROBE
ASP

CAGGAGACAGAGATGAGAA
[5TET]ACAGTTCTATCTCTTCTTCAG[BHQ1a-Q]
GGAGTGATGGCAGTAGAC

TUBB3

SP
PROBE
ASP

CATCCAGGAGCTGTTCAA
[AminoC6+TxRed]CGCATCTCCGAGCAGTTCAC[BHQ2aQ]
GTCGTTCATGTTGCTCTC

NSE

SP
ASP

TGAGGGATGGAGACAAAC
GAGACCTGAGCTGATGAG

GFAP

SP
ASP

Glial genes
CCGTCTGGATCTGGAGAG
TCCTCCTCGTGGATCTTC

GLT-1

SP
ASP

GACAGTCATCTTGGCTCAG
GAGCAGCAGATTCTTCCC

Figure 3. Primer sets used in the present study including sense (SP) and
antisense primers (ASP). For multiplex assays, probe sequences are given.
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2.6 mtDNA copy number
MtDNA copy number was determined using a four-color multiplex qPCR assay
targeting human mtDNA-encoded genes around the mitochondrial genome (12s rRNA,
ND2, CO3, ND4). Absolute quantification of DNA samples was based on human mtDNA
copy number standards run on the same plate. The mtDNA standards were prepared as
described previously [129]. Briefly, human genomic DNA was purchased from Roche
and treated with limiting amounts of Plasmid-Safe ATP-dependent DNase (Epicentre
Biotechnologies, Madison, WI) according to manufacturer recommendations. This
procedure selectively digests all forms of DNA but does not affect closed circular or
nicked circular double-stranded DNA, leaving only circular mtDNA. MtDNA was further
purified according to protocols for the UltraClean GelSpin DNA purification kit (MO BIO
Laboratories, Calsbard, CA) and quantified with a DNA Quant-iT assay kit (Invitrogen,
Calsbard, CA) and the linear band was visualized on a 0.8% agarose gel.

2.7 Confocal microscopy and immunofluorescence
For immunocytochemistry analysis cells were seeded in 35 mm glass bottom
confocal dishes. On D21 cells were fixed in 4% paraformaldehyde and 4% sucrose in
PBS at room temperature for 15 minutes. Cells were incubated for 60 minutes in
blocking buffer (5% goat serum, 1% BSA, 0.1% Triton-X in PBS). Cells were incubated
overnight at 4°C with primary antibody (1:100) diluted in 5% goat serum. Primary
antibodies included rabbit anti-ChAT (Millipore), mouse anti-nestin (abcam), mouse antiTOMM20 (abcam), mouse anti-Isl1/2 and HB9 (MNR2; DHSB), and rabbit anti-MAP2
(Millipore). Alexa Fluor conjugated secondary antibodies (1:400, Life Technologies)
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were added for 60 minutes at room temperature. After washes, VECTASHIELD
mounting media with DAPI was added for visualization of nuclei. Images were obtained
with an Olympus FV1000 confocal microscope. For TOM20 and percent positive
quantitation, ten representative fields were taken and analyzed using MetaMorph image
analysis software (Molecular Devices). For TOMO20 staining pixel values were
normalized to number of cells in each image, identified by DAPI nuclear staining.

2.8 Western blot analysis
Cell homogenates were prepared by dissociating cells with TrypLE™ and
washing three times with PBS. After the last wash samples were resuspended in RIPA
buffer (50 mM Tris-HCl, 1% NP-40, 0.25% Na deoxycholate, 150 mM NaCl, 1 mM
EGTA, 1 mM Na orthovanadate, 1 mM Na fluoride, pH 7.4) with 10 ul/ml Protease
Inhibitor Cocktail Set I (Calbiochem) and 10 ul/ml of 100 mM PMSF (Sigma), followed
by water bath sonication for 2 minutes. Samples were incubated on ice for 30 minutes
and vortexed every 5 minutes prior to centrifugation at 15,000 x g for 10 minutes at 4°C
to remove cellular debris. The supernatant was transferred to a new microcentrifuge
tube and stored at -20°C for later analysis.
Equal concentration (20-25 ug) of total cell protein from each sample was
separated on a 4-12% Bis-Tris Criterion precast gel at 200 V for 1 hour using sodium
dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE). The proteins were
transferred to nitrocellulose membranes using the iBlot transfer system (Invitrogen).
After blocking the membrane for 1 hour with Odyssey® blocking buffer (LI-COR
Biosciences) the membrane was probed primary antibody overnight at 4°C. Primary
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antibodies were diluted in blocking buffer with 0.1% Tween 20 and included the
MitoProfile® Total OXPHOS Human WB Antibody Cocktail (1:200, ab110411, Abcam),
mouse anti-VDAC1 (1:1000, Abcam), and rabbit anti-beta actin (β-actin; 1:500, Abcam).
The membrane was probed with 800CW goat anti-mouse or 680 goat anti-rabbit
secondary antibodies (1:15000, LI-COR) at RT for 1 hour and band intensity was
quantified using the Odyssey infrared imaging system (LI-COR, Lincoln, NE).

2.9 XF24 extracellular flux analyzer
Cell metabolic rates were measured using an XF24 Extracellular Flux Analyzer
(Seahorse Bioscience) in unbuffered DMEM, pH 7.4 as described previously by our
group [130]. Briefly, on day 16 cells were seeded onto an XF24 Cell Culture Microplate
(Seahorse Bioscience) at 60,000 cells/well with 10 µM Y-27632 dihydrochloride, a
selective inhibitor of Rho-associated protein kinase (ROCK; Tocris) and incubated at
37°C in 5% oxygen. After 3 days hNSCs were seeded onto the same XF24 Cell Culture
Microplate at 40,000 cells/well with 10 µM ROCK inhibitor and incubated at 37°C 5%
oxygen for 24 hours. iPSC-derived cells (D0 and D21) were plated at 60,000 cells/well
the day before recording. Each cell type was tested at three to four concentrations to
determine the most reliable plating density. Inhibitors included oligomycin (1 µM) and
FCCP (0.5-1 µM). OCR and ECAR were normalized to protein concentration (Micro
BCA Kit, Pierce) for all experiments to account for differences in cell size.
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2.10

Lentiviral generation and infection
For generation of the HB9::GFP lentivirus services and products generated by

the VCU Massey Cancer Center Biological Macromolecule Shared Resource,
supported, in part, with funding from NIH-NCI Cancer Center Support Grant P30
CA016059 were used. Addgene plasmid 37080 [124] was cotransfected with packaging
and envelope plasmids cCMVR8.74 and MD2G. Transfection and viral concentration
were performed using standard published protocols. Virus titer was 5 x 10^7 TU/mL in
PBS. Cells were infected at a multiplicity of infection (MOI) of 3-5 with 8 ug/ml protamine
sulfate 5 days before recording.

2.11

Electrophysiology
For whole-cell patch-clamp experiments cells were differentiated for 28 days.

Two days before recording cells were moved to 12 mm diameter circular glass
coverslips (neuvitro). On the day of recording coverslips were placed in a recording
chamber on the stage of an inverted microscope (Olympus). An Axopatch 200B
amplifier (Molecular Devices) and pClamp 10 software (Axon Instruments) were used to
record whole-cell currents. Patch pipettes were pulled from thick-walled borosilicate
glass capillaries to resistances of 2-4 mΩ and filled with internal solution containing 120
mM KCl, 2 mM MgCl2, 1 mM CaCl2, 10 mM EGTA, 10 mM HEPES, 2 mM Na2ATP (pH
7.2). Extracellular solution consisted of 135 mM NaCl, 5 mM KCl, 2 mM MgCl2, 1 mM
CaCl2, 10 mM HEPES, and 10 mM glucose (pH 7.4). Action potential threshold was
determined as the voltage at which the d(V)/d(T) function deviated from zero. Action
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potential height was determined by measuring the threshold to the peak of the action
potential.

2.12

Statistical analysis

All results are expressed as the mean ± standard error of the mean (SEM). The
number of experiments performed is denoted by n. Outliers were excluded at the
p<0.05 level by Grubbs’ test. Statistics were calculated using one-way ANOVA or
unpaired t-test in Prism software (GraphPad, Prism). P-values <0.05 were considered
statistically significant.
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CHAPTER THREE
Generation of motor neurons from embryonic and iPSC-derived human neural
stem cells
3.1 Rationale and Hypothesis
The present study tested the ability of factors crucial for the patterning of motor
neurons in the developing spinal cord to differentiate human neural stem cells (hNSCs)
into motor neurons in culture. This will allow for the study of a cell type currently only
accessible in post mortem tissue or in animal models. Additionally, reprogramming cells
from patients may prove beneficial in the modeling of complex diseases with no single
genetic cause, including ALS. Since iPSCs have the same genetic profile as living
patients they may replicate disease pathology. There is evidence that disease
processes begin decades before symptom onset, so these ‘young’ cells may give us
insights into disease mechanisms.
Previous studies have differentiated hESCs and iPSCs derived from fibroblasts
into motor neurons [91-97, 128, 131-134]. As summarized in Figure 4, this study uses
human embryonic stem cells (hESCs) and induced pluripotent stem cells (iPSCs) from
healthy individuals and lays the groundwork for replicating these studies using patient
cells. Peripheral blood mononuclear cells (PBMCs) were used for reprogramming
instead of fibroblasts (Figure 4). iPSCs derived from PBMCs display an epigenetic
profile closer to hESCs than iPSCs derived from fibroblasts [89] and PBMCs are
exposed to fewer environmental mutagens. Previous studies have shown that PBMCs
can be reprogrammed into iPSCs but it remains to be shown if they can differentiate into
motor neurons.
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Figure 4. Schematic of motor neuron differentiation. Neural stem cells from hESC
and iPSC-derived cells will be differentiated into motor neurons
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3.2 Statement of contributions
This chapter contains data collected by three individuals. Amy Ladd generated
that data represented in Figure 5 showing mtDNA encoded gene expression in ALS and
control PBMCs. This figure was reproduced from a recent publication from our lab [26].
For iPSC generation Amy Ladd and I isolated PBMCs from peripheral blood and Paula
Keeney performed all of the cell culture work to generate the iPSC cell line (Figure 6
and 7B). I performed all cell culture and experiments with the H9 hESC-derived cell line
and the iPSC cell line after neural induction (Figures 7A, 9, and 10)

3.3 Results
3.3.1 Generation of iPSCs from PBMCs.
Peripheral blood samples from nine sporadic ALS (sALS) patients and 11 controls
were collected according to an IRB approved protocol. If possible, spouses were used
as controls. This allowed for a convenient, relatively age-matched, gender balanced
control group. Additionally, these individuals likely lived together and would therefore be
exposed to a similar environment. Although ALS iPSCs are not used in this study,
isolated PBMCs are frozen for future reprogramming use from all patients.
Following isolation, PBMCs were cultured for two weeks in conditions favoring
erythroblast expansion and eliminating lymphocytes. This is an important step, as
lymphocytes (70-90% of PBMCs) commonly rearrange their DNA and thus stem cell
lines derived from them may have an increased rate of forming lymphomas [135].
Additionally, this culture protocol enriches for CD34+ hematopoietic stem cells without
the need for cell sorting. Interestingly, PBMCs from ALS patients have decreased
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mitochondrial DNA encoded gene expression compared to controls [26]. This mirrors
what is seen in post mortem spinal cord from sALS patients[26] and may suggest a
systemic bioenergetic impairment in these individuals. These findings, along with
decreased growth rates and survival of the sALS iPSC cell lines support the hypothesis
that ALS cells may be more sensitive to stress, as seen in familial ALS (fALS) derived
cells [93].
As described in Figure 4, after expansion, PBMCs were reprogrammed into iPSCs
by electroporation of five reprogramming factors, Oct4, Sox2, Klf4, c-Myc, and Lin28 as
well as a plasmid containing the SV40 large T antigen. As shown in Figure 5A, two
weeks after reprogramming live cells express TRA-1-60, a human stem cell antigen and
early marker of pluripotency. As iSPC colonies formed, starting at day 21, they were
identified and expanded. To confirm pluripotency of the iPSC cell line, three colonies
were chosen for qPCR analysis. Figure 5B shows increased expression of genes
encoded by the reprogramming plasmid including Oct4, Sox2, and Lin28 in iPSC
colonies compared to PBMCs (Figure 5B; *p<0.05, **p<0.01).
After 10 days in neural induction media, NSC colonies were picked and expanded.
qPCR revealed decreased expression of the plasmid encoded genes Oct4, Sox2, and
Lin28 in NSCs (Figure 5B; *p<0.05, **p<0.01). This suggests that the plasmid is no
longer being expressed.
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Figure 5. Generation of iPSCs from blood A) Expression of TRA-1-60, an early
marker of pluripotency, after reprogramming B) Expression of genes encoded by the
reprogramming plasmid in peripheral blood mononuclear cells (PBMCs), induced
pluripotent stem cells (iPSCs), and neural stem cells (NSCs) (*p<0.05, **p<0.01). SOX2
expression was undetectable in PBMCs
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3.3.2 Neural induction of iPSCs
In order to confirm successful neural induction of iPSCs, cells were stained with the
human neural stem cell (hNSC) marker, nestin. Nestin is an intermediate filament
protein expressed in neuroepithelial precursors that become neurons and glia [136]. A
representative confocal image is shown in Figure 6A. 67% of cells stained positive for
nestin. To test if iPSC-derived hNSCs display an early commitment to a particular
lineage, expression of a panel of neuronal and glial genes were assessed by qPCR.
Neuronal markers neural filament light chain (NEFL), microtubule-associated protein 2
(MAP2), and beta III tubulin (TUBB3) increased expression during neural induction
(Figure 6B; *p<0.05).
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Figure 6. Neural induction of iPSCs. A) A representative confocal image showing
expression the neural stem cell marker nestin (green) and DAPI nuclear staining (blue)
after neural induction B) qPCR analysis of neuronal markers in iPSCs and after neural
induction (*p<0.05)
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3.3.3 Spontaneous differentiation of NSCs into neurons, astrocytes and
oligodendrocytes
While the iPSC cell line was being established, experiments were performed using
commercially available hNSCs. The hNSC line used is derived from NIH approved H9
(WA09) hESC cells. These cells have a normal human female karyotype and can
remain in an undifferentiated state in the presence of growth factors or can differentiate
into neurons, astrocytes or oligodendrocytes. Starting from hNSCs instead of hESCs
allowed for an accelerated differentiation protocol since neural induction had already
been completed. In addition, these cells are easier to culture since they are adherent,
compared to hESC and iPSCs, which are often cultured and differentiated as floating
embroyid bodies. Over 90% of these cells stained positive for the neural stem cell
marker nestin on day 0 (D0; Figure 7). Many D0 cells also stained positive for the
neuronal marker MAP2 but did not stain positive for the glial markers GalC or GFAP
(Figure 7).
In order to test the differentiation capacity of hNSCs, growth factors bFGF and EGF
were withdrawn from cell culture media for 14 days. This resulted in loss of nestin
staining and spontaneous differentiation of cells into neurons (MAP2+),
oligodendrocytes (galactocerebroside, GalC+), and astrocytes (GFAP+; Figure 7).
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Figure 7. Neuronal and glial markers after spontaneous differentiation. Expression
of the neural stem cell marker nestin, the neuronal marker MAP2, and the glial markers
GALC and GFAP at day 0 (D0) and day 14 (D14) after spontaneous differentiation in
hESC-derived cells
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3.3.4 Motor neuron differentiation of hESC-derived cells
To test the ability of commercially available hNSCs to differentiate into
specialized cell types we induced motor neuron differentiation with retinoic acid (RA)
and purmorphamine (PM), a sonic hedgehog (SHH) agonist. SHH has been shown to
regulate ventralization of neural tissues [35]. As shown in Figure 8A, qPCR analysis
revealed that after 21 days of differentiation (D21) cells significantly increased
expression of post mitotic motor neuron genes ISL1 and HB9 (t-test D0 vs D21,
*p<0.05, **p<0.01). Phase contrast images on D21 revealed morphological changes
including an extensive network of processes (Figure 8B). On D21 46% of cells stained
positive for both MAP2 and HB9 and 51% stained positive for MAP2 and ISL1/2 (Figure
8C). GFAP staining was not observed in these cultures. Collectively, these findings
suggest that cells acquire a motor neuron molecular phenotype by D21. Analysis
comparing different passage numbers revealed that higher passage numbers resulted
in more variable gene expression data, therefore all data were generated from cells with
passage numbers less than 33.
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Figure 8. Motor neuron differentiation of hESC-derived hNSCs. A) qPCR
expression of spinal motor neuron markers HB9 and ISL1 on day 0-28 (D0-D28) of
motor neuron differentiation (*p<0.05, **p<0.01) B) Representative phase contrast
images of D0 and D21 cells C) Immunostaining of MAP2 (red), HB9 or ISL1 (green),
and DAPI (blue) on D0 and D21
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3.3.5 Differentiation of motor neurons from iPSC-derived cells
For motor neuron differentiation of iPSC-derived cells the protocol was modified
based on a recent publication [128]. The differentiation schematic is shown in Figure
9A. RA and PM concentrations remained the same, but small molecules SB435142
(SB) and LDN193189 (LDN) were used to induce neuralization by inhibition of SMAD
signaling. Smoothened agonist (SAG) was added in addition to PM to further increase
sonic hedgehog signaling. For increased neurotrophic support, GDNF and CNTF were
added after day 14. Preliminary data revealed wide variations in gene expression in
cells of different passage number; therefore all cells were cultured for a minimum
amount of time, 4-6 days after thawing, before motor neuron differentiation was started.
Figure 9B shows representative phase contrast images of D0 and D21 cells and is very
similar to what was seen in hESC-derived cells. Expression of motor neuron markers
HB9 and ISL1 were undetectable in D0 cells by qPCR and increased significantly on
D21 (Figure 9C; **p<0.01, ***p<0.001). The expression of vesicular acetylcholine
transporter (VACHT) was also significantly increased on D21 compared to D0,
suggesting that these cells are cholinergic neurons (Figure 9C). To further confirm
motor neuron identity, cells were stained with HB9, ISL1/2, and MAP2. Figure 9D
shows staining for these markers on D21 but not on D0.
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Figure 9. Motor neuron differentiation of iPSC-derived hNSCs. A) Schematic of the
motor neuron differentiation protocol showing timing of neuralization with SB and LDN,
caudalization with RA, induction of sonic hedgehog signaling with SAG and PM, as well
as neurotrophic support from day 14 on with CNTF and GDNF B) Representative phase
contrast images of D0 and D21 cells C) Expression of motor neuron genes HB9, ISL1,
and VACHT (**p<0.01, ***p<0.001) D) Immunostaining of MAP2 (red), HB9 or ISL1
(green), and DAPI (blue) on D0 and D21
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3.4 Summary
In summary, these studies demonstrate the ability to generate iPSC cell lines
from PBMCs without viral expression or DNA integration of plasmid. The finding of
decreased mtDNA encoded gene expression in sALS PBMCs suggests that these cells
may replicate disease pathology since this mirrors what is seen in post mortem spinal
cord from sALS patients. Secondly, commercially available hNSCs were differentiated
into multiple neuronal cell types, including motor neurons. This accelerated protocol,
without the need for suspension culture, may prove to be advantageous in labs without
access to or experience with culturing stem cells. Finally, iPSCs were successfully
induced to become motor neurons, based on multiple gene and protein markers. These
cells may be used to understand human motor neuron physiology. Collectively, these
studies set the stage for the study of human motor neurons and reprogramming and
differentiation of ALS patient cells in the future.
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CHAPTER FOUR
Mitochondrial biogenesis increases as cells differentiate from neural stem cells
into motor neurons

4.1 Rationale and Hypothesis
Previous studies have demonstrated that both hESCs and iPSCs produce ATP
mainly through glycolysis and that during differentiation there is a switch to energy
production by oxidative phosphorylation (OXPHOS). The mechanism underlying this
switch remains unknown, but an increase in mitochondrial mass, mtDNA copy number
and ATP production has been seen during spontaneous differentiation of hESCs into all
three germ layers [108, 109]. Based on these findings, this series of experiments
hypothesized that mitochondrial biogenesis would increase during motor neuron
differentiation. Mitochondrial biogenesis is the process by which cells increase their
mitochondrial components and includes upstream mRNA signaling, mtDNA copy
number and gene expression, electron transport chain protein expression, and
mitochondrial mass. Although many of these processes are regulated by the same
mechanisms, they may also act independently of each other, resulting in an increase of
one without an increase in all of them. Figure 10 depicts how mitochondrial biogenesis
‘master regulator’ PGC1-α increases transcription of genes encoding mitochondrial
proteins as well as mitochondrial and non-mitochondrial sources of cellular ATP
production.
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Figure 10. Mitochondrial biogenesis and ATP production. A) Anaerobic glycolysis is
the process by which glucose is converted to pyruvate. Pyruvate can be converted into
lactate anaerobically or oxidatively decarboxylated by the TCA cycle to electrons (e-)
that reduce NAD+/FAD+ to NADH/FADH which are then oxidized by the electron
transport chain (ETC) to generate ATP during oxidative phosphorylation (OXPHOS) B)
Mitochondrial biogenesis regulator PGC-1α binds to NRF1/2 and ERRα, initiating gene
expression of mitochondrial components.
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4.2 Results
4.2.1 Mitobiogenesis signaling increases with motor neuron differentiation
In order to assess mitochondrial biogenesis as cells differentiate from hESCderived hNSCs to motor neurons, qPCR targeting biogenesis genes was performed at
seven-day time points. Figures 11A and B shows increased levels of PGC-1α at D21,
POLG at D28, and ERRα, NRF1 and POLRMT at D21 and D28 compared to D0 (n=4-6,
p<0.01, one-way ANOVA, *p<0.05, **p<0.01, ***p<0.001, Dunnett’s multiple
comparisons test). NRF2, TFAM, and TFMB2 expression remained unchanged (p<0.05,
one-way ANOVA). Based on these findings D21 was chosen as the time point for
analysis of iPSC-derived cells. There was no change in PGC-1α, POLG, POLRMT, or
TFAM expression but there was an increase in ERRα at D21 in iPSC-derived cells
(Figure 11C; n=3, *p<0.05, unpaired t-test).
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Figure 11. Mitochondrial biogenesis signaling during motor neuron
differentiation. Expression of upstream (A) and downstream (B) mitochondrial
biogenesis genes in hESC-derived cells at D0 (hNSCs) and on day 7-28 of motor
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4.2.2 Mitochondrial encoded genes increase with motor neuron differentiation.
The nuclear genome encodes most of the proteins that mitochondria require;
however, mitochondria have their own genome that encodes 13 proteins essential for
respiratory chain function. To determine if mitochondrial gene expression was increased
during motor neuron differentiation we measured with qPCR expression of four mtDNAencoded genes. Figure 12A shows an increase in ND2 and ND4 expression on D21
and D28 compared to D0 in hESC-derived cells (n=4-6, *p<0.05, one way ANOVA,
*p<0.05, Dunnett’s multiple comparisons test). However, there was no statistically
significant increase in iPSC-derived cells on D21 compared to D0 because of variability
in the D21 samples (Figure 12B, n=3, p>0.05, unpaired t-test).
qPCR was also performed with genomic DNA as the input. When analyzed using
a standard curve of human mtDNA samples we were able to determine the mtDNA copy
number. This analysis revealed a non-significant decrease in mtDNA copy number in
hESC-derived cells (Figure 12C), as well as a significant decrease in mtDNA copy
number in iPSC-derived cells with motor neuron differentiation (Figure 12D; *p<0.05).
Because the four genes chosen are spatially distributed around the mitochondrial
genome we are also able to detect mtDNA deletions using this method. Since there are
no differences in the expression levels of the four genes at any time point we know that
there are likely no major mtDNA deletions in those areas.
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4.2.3 Glycolysis decreases as cells differentiate into motor neurons
For respiration analysis oxygen consumption rate (OCR) and extracellular
acidification rate (ECAR) were measured simultaneously in adherent cultures using the
XF24 Extracellular Flux Analyzer. This instrument allows measurement from 20 wells of
cells plus 4 control wells. ECAR is measured in milli-pH units (mpH) and measures the
change in pH resulting from the release of protons from the cell during glycolysis. In
order for these readings to be accurate they must be within the linear range of the XF24
instrument. In order to determine optimal cell density three or four densities, ranging
from 20,000 to 80,000 cells per well, were measured for each cell type. The iPSC cell
line is denoted C42 here. Figure 13 shows basal OCR and ECAR as a function of cell
number. As seen with both hNSC lines (H9 D0 and C42 D0), 80,000 cells per well gives
signals beyond the linear range of the XF24 instrument (Figure 13A and C). Based on
these data as well as variability between wells (data not shown), we chose 40,000 cells
per well for H9 D0 and 60,000 cells per well for H9 D21, C42 D0, and C42 D21.
In order to assess electron transport chain function, a number of inhibitors are
commonly used including oligomycin, FCCP, rotenone, and antimycin A. Oligomycin is
added to inhibit ATP synthase, followed by the protonophore FCCP to dissipate the
proton gradient and measure maximal OCR in an uncoupled state, rotenone to inhibit
complex I and antimycin A to inhibit complex III. Starting concentrations of these
inhibitors were chosen based on published protocols [130, 137]. Interestingly, the
starting concentration of 0.3 µM FCCP was insufficient to uncouple respiration in both
hESC- and iPSC-derived cells. Since an excess of FCCP can uncouple the plasma
membrane, it was important to determine the lowest concentration required to uncouple
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mitochondrial respiration. 0.5-2 µM FCCP were tested in both cell types optimal
concentration was chosen based on an increase from oligomycin inhibited levels (0.5
µM for hESC-derived and 1 µM for iPSC-derived). Interestingly, no concentration of
FCCP increased OCR above basal levels in either cell type. This suggests that cells are
respiring at maximum capacity.
Figure 14A shows a representative recording of iPSC-derived cells on D0
(green) and D21 (blue). Temperature control wells are shown in teal. Dotted lines
represent an average of the three time points. Respiration analysis was performed on
hESC- (Figure 14B) and iPSC-derived cells (Figure 14C). There was no change in
basal respiration or after addition of any of the inhibitors on D21 compared to D0 in
either cell type (p>0.05, unpaired t-test). We did not detect changes in oxygen
consumption coupled to ATP synthesis or max respiratory capacity in either cell type.
ECAR was measured simultaneously in these cultures. There was a significant
decrease in ECAR at D21 compared to D0 in both hESC-derived cultures (Figure 15A),
as well as iPSC-derived cultures (Figure 15B; *p<0.05). This suggests a decreased
usage of glycolysis in motor neurons compared to hNSCs.
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4.2.4 Electron transport chain proteins, but not mitochondrial mass, increase with
differentiation
To further investigate mitochondrial biogenesis as hNSCs differentiate into motor
neurons we measured protein expression of electron transport chain proteins. As shown
in Figure 16B, in hESC-derived cells, levels of complex II (CII) and complex V (CV)
proteins were significantly increased on D21 and D28, respectively (n=3-4). All other
proteins were increased at both time points but did not reach statistical significance. To
increase statistical power, respiratory proteins normalized to their representative D0
were combined and this revealed a significant increase on D21 and D28 (Figure 16C).
In iPSC-derived cells there was a significant increase in complex III (CIII) and complex
V (CV) on D21 (n=4, Figure 16E). When combined, respiratory proteins were
significantly increased on D21 (Figure 16F).
To measure mitochondrial mass protein expression of an outer mitochondrial
membrane protein, voltage-dependent anion channel 1 (VDAC1), was analyzed.
Interestingly, the VDAC1 protein levels were unchanged in hESC-derived cells on D21
and D28 (Figure 17A) and iPSC-derived cells on D21 compared to D0 (Figure 17B).
To further confirm that mitochondrial mass is unchanged during motor neuron
differentiation, hESC-derived cells were immunostained for the translocase of outer
mitochondrial membrane, TOM20. Localization of mitochondria changed from
perinuclear in hNSCs to extended into long processes on D21. However, when TOM20
fluorescence in 10 representative fields was normalized to cell number there was no
difference in fluorescence between D0 and D21 (Figure 17D).
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Figure 16. Respiratory chain protein expression in hNSCs and motor neurons. A)
Representative western blot of hESC-derived cells B) Western blot quantitation
normalized to beta actin C) Respiratory chain protein expression in hESC-derived cells
D) Representative western blot of iPSC-derived cells E) Quantitation normalized to beta
actin F) Respiratory chain protein expression in iPSC-derived cells. *p<0.05, **p<0.01,
***p<0.001
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4.3 Summary
In summary, this series of experiments demonstrated that mitochondrial
biogenesis signaling and electron transport chain protein expression increases during
motor neuron differentiation of hNSCs. This is not accompanied by an increase in
mtDNA copy number or mitochondrial mass, suggesting that the total amount of
mitochondria in the cell is not changing. Although there is no change in respiration rates
there is a significant decrease in glycolysis between hNSCs and motor neurons.
Together, these results indicate that mitochondrial biogenesis is increased during motor
neuron differentiation and is accompanied by a reduction in glycolysis.
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CHAPTER FIVE
Electrophysiological changes as cells differentiate into motor neurons

5.1 Rationale and Hypothesis
Development of voltage-activated currents and the generation of action potentials
are crucial to motor neuron maturation in vivo. In order to explore these properties in
vitro we performed whole cell patch clamp on hESC- and iPSC-derived motor neurons.
We expected that after four weeks of motor neuron differentiation cells would display
currents characteristic of excitable cells and generate action potentials following
depolarizing current injection. These findings will set the stage for further analysis of
voltage gated ion channels underlying motor neuron excitability in healthy and disease
states.

5.2 Results
5.2.1 Identifying motor neurons in live culture
In order to identify motor neurons in live cultures a lentivirus was generated with
GFP under control of a motor neuron specific transcription factor (HB9). To increase the
rate of viral infection, cells were treated with the cationic polymer protamine sulfate. This
polymer was chosen over polybrene, a commonly used viral infection enhancer,
because this latter agent was toxic to motor neurons used in this study. Optimal
multiplicity of infection (MOI) and virus incubation time was determined for each cell
type. Cells were infected with the lentivirus 5 days before recording and replated on
glass coverslips 2 days before recording.
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5.2.2 Passive membrane properties of hESC and iPSC-derived cells
Passive membrane properties were recorded after the whole cell patch clamp
configuration was acquired and monitored over the course of the recording on day 28 of
motor neuron differentiation. Membrane capacitance (Cm) was 14.88 ± 1.42 pF for
hESC-derived cells (n=5) and 9.75 ± 0.45 pF for iPSC-derived cells (n=7; Figure 18A).
Resting membrane potential (Vm) was -39 ± 3.84 mV (n=6) in hESC- and -31.6 ± 4.82
mV (n=10) in iPSC-derived cells (Figure 18B). Membrane resistance (Rm) was 2±0.3
GΩ in hESC-derived cells (n=5) and 3.77±0.85 GΩ in iPSC-derived cells (n=6; Figure
18C). None of these parameters were statistically different between cell types.
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Figure 18. Passive membrane properties in hNSC-derived motor neurons. A)
Membrane capacitance (Cm), B) Resting membrane potential (Vm), and C) Membrane
resistance (Rm) in hESC- and iPSC-derived motor neurons.
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5.2.3 Voltage gated currents characteristic of excitable cells
A series of voltage steps from a holding potential for -60 revealed inward and
outward currents characteristic of sodium and potassium currents, respectively. Figure
19A (i) shows a representative recording from an iPSC-derived motor neuron on D28.
The presence of sodium channels was confirmed by the addition of 2 µM tetrodotoxin
(TTX, Figure 19A (ii)). In order to determine current densities normalized to cell size,
peak current amplitude was divided by cell capacitance. Mean sodium current density
was -29.10 ± 8.29 pA/pF (n=5) for hESC-derived cells and -37.51 ± 5.39 pA/pF (n=7) for
iPSC-derived cells (Figure 19B). Mean potassium current density was 29.55 ± 9.25
pA/pF (n=5) for hESC-derived cells and 78.91 ± 8.04 pA/pF (n=7) for iPSC-derived cells
(Figure 19C). Interestingly, iPSC-derived motor neurons had a significantly higher
potassium channel density than hESC-derived cells.
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5.2.4 Action potential firing of stem cell derived motor neurons
Action potentials were elicited by a series of current pulses of increasing injected
current amplitude under the current clamp mode of the patch clamp technique.
Approximately 40% of hESC-derived cells and 60% of iPSC-derived cells fired action
potentials on D28. A representative trace from a hESC-derived cell is shown in Figure
20A. After action potential generation was confirmed, the minimum amount of current
injection necessary to generate an action potential, rheobase, was determined by
increasing the current injection by 0.01 nA. Rheobase was 23.75 ± 9.44 pA in hESCderived motor neurons (n=4) and -10.75 ± 11.88 pA in iPSC-derived motor neurons
(n=4; p>0.05; Figure 20B). The fact that some iPSC-derived cells fire action potentials
after hyperpolarizing current injection suggests the ability for spontaneous action
potential formation. The threshold potential for the upstroke of the action potential and
action potential height was similar for both cell types (Figure 20B).
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and AP height for both cell types
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5.3 Summary
Taken together, these preliminary results provide evidence that cells develop
voltage gated channels characteristic of excitable cells and are able to generate action
potentials on D28 of motor neuron differentiation. Similar effects were seen in hESCand iPSC-derived cells. Combined with mRNA and protein analysis, these findings
suggest that hNSC-derived cells are developing into functional motor neurons. These
studies set the stage for future analysis of stem cell derived motor neurons including the
alteration of excitability by pharmacological means.
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CHAPTER SIX: DISCUSSION

6.1 Generation of motor neurons from hNSCs
The goal for the first set of studies was to generate motor neurons from hNSCs.
In order to develop a protocol for patient cell use we reprogrammed PBMCs into iPSCs.
Following neural induction 67% of these cells stained positive for the hNSC marker
nestin. These cells, as well as commercially available hESC-derived hNSCs (>90%
nestin positive) were further differentiated into motor neurons. After 21 days of motor
neuron differentiation cells had significantly increased expression of genes normally
found in motor neurons including the motor neuron specific transcription factor HB9.
~45% of hESC- and ~10% of iPSC-derived cells co-stained positive for markers of postmitotic spinal motor neurons and a more general neuronal marker. The findings in
hESC-derived cells were consistent with a previous study using a similar protocol which
reported ~30% motor neurons, but iPSCs showed a much lower rate of motor neuron
generation. These results demonstrate for the first time that iPSCs derived from PBMCs
can differentiate into motor neurons.
There was a higher percentage of motor neurons in hESC- compared to iPSCderived cultures (~45% vs ~10%, respectively). This may be due to more efficient neural
induction since hESCs were >90% nestin positive compared to 67% in iPSC-derived
cells. This could be also be due to changes in the protocol including a shortened
embryoid body stage and only four days of dual SMAD inhibition compared to seven in
the previous study [128].
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Motor neurons derived from hPSCs give us the ability to study a cell type
previously only accessible in post mortem tissue. However, the artificial environment in
which they are grown has limitations. We have shown that retinoic acid (RA) and
purmorphamine (PM) exposure is sufficient to induce motor neuron differentiation in
hESC-derived cells but there are a number of other signaling molecules present in the
developing embryo that were not added in vitro. In order to more closely replicate
physiological conditions for the iPSC-derived motor neuron differentiation protocol, we
added small molecules to inhibit SMAD signaling and BDNF during early differentiation
and GDNF/CNTF for trophic support after day 14. Previous studies have shown that
SMAD inhibition efficiently neutralizes hNSCs [138, 139]. Another artificial aspect of this
culture environment is that it does not allow motor neurons to interact with other cell
types including glia. The lack of GFAP staining is consistent with a previous study using
a similar protocol [128] and suggests that there are no astrocytes, but we did not
perform oligodendrocyte staining. Furthermore, these motor neurons do not form
functional synapses with muscle, their in vivo targets. Previous studies have shown the
ability of hESC- and iPSC-derived motor neurons to make functional synapses on
muscle cells in culture but we do not yet know how this affects motor neuron maturation
and firing. Finally, traditional cell culture grows cells in a single layer, compared to the
three dimensional nature of tissue. There has been recent interest in developing threedimensional cell culture systems but much work remains if this is to be a feasible model
for more than a few select labs (for a review see [140]. A three-dimensional culture
system would provide the spatial organization of tissue, in addition to allowing more
accurate gradient signaling important during development.
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PBMCs were chosen as starting material for reprogramming over fibroblasts,
which are more commonly used. Collecting peripheral blood is a much simpler and less
invasive procedure than a skin punch for fibroblast collection. Since these cells are not
exposed to environmental mutagens they may be clinically more favorable due to less
DNA mutations. Furthermore, PBMCs have a DNA methylation profile that more closely
resembles hESCs [89], suggesting that they may reprogram more easily. Indeed, a
previous study found that PBMCs could be reprogrammed with greater efficiency and
two weeks faster than fibroblasts [89]. PBMCs may also more accurately replicate
disease pathology. The current study showed that PBMCs from sALS patients had less
mtDNA encoded genes compared to control patients [26]. This replicates what is seen
in post mortem spinal cord of ALS patients [26]. Blood cells are unaffected in ALS and
this decrease in mitochondrial gene expression may represent a systemic bioenergetic
impairment that has not been previously characterized. If motor neurons derived from
these cells share the same decreased expression they may be a useful model of sALS.
Furthermore, if mtDNA gene expression is consistently decreased in all ALS patients
this panel of genes may be used as a biomarker for ALS.

6.2 Mitobiogenesis signaling in hPSC-derived motor neurons
The goal for this series of experiments was to investigate mitochondrial
biogenesis during motor neuron differentiation. Gene expression of mitochondrial
biogenesis ‘master regulator’ PGC-1α and many of its downstream targets were
increased in hESC-derived cells during differentiation and expression peaked on day
21. This is consistent with PGC-1α activating ERRα and NRF1 to increase transcription
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of downstream POLG and POLRMT. Expression of mitochondrial transcription factors
TFAM and TFMB2 was unchanged, consistent with no significant change in mtDNA
copy number in these cells. iPSC-derived cells increased expression of ERRα on day
21. The finding that not all mitobiogenesis genes were increased could mean that these
cells increase mitobiogenesis gene expression earlier or later in the differentiation
process, given that only one time point was analyzed in these cells. Expression of two
mtDNA-encoded genes, ND2 and ND4, was also increased in hESC-derived cells on
D21. However, there was too much variation in iPSC-derived samples to determine a
statistically significant increase. In contrast, mtDNA copy number was decreased
slightly in hESC- and significantly decreased in iPSC- derived motor neurons.
Respiration analysis revealed no change in basal respiration between hNSCs
and motor neurons, but there was a decrease in glycolysis. One limitation of this series
of studies is that cells were grown and differentiated in 5% oxygen but respiration
analysis was performed in room air (~20% oxygen). Efforts were made to keep D0 and
D21 cells in as similar conditions as possible (similar passage number, similar time in
culture, etc.) but the change in oxygen concentration may have affected the cells.
Interestingly, neither D0 nor D21 cells increased OCR levels above basal after the
addition of FCCP. FCCP uncouples the proton gradient across the inner mitochondrial
membrane, measuring maximum oxygen consumption. The fact that this value never
exceeds basal levels suggests that the ETC is already running at maximum capacity in
both cell types.
Although a decrease in glycolysis may result in increased OXPHOS, it doesn’t
necessarily mean there is an increase in mitochondrial mass. Mitochondrial mass could
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remain the same but there could be more ETC complexes or they could be more
efficient in OXPHOS. Indeed, we found an increase in respiratory proteins but no
increase in mitochondrial mass. The proteins increased included complex II and V in
hESC-derived cells and complex III and V in iPSC-derived motor neurons compared to
hNSCs. One limitation of measuring ETC proteins this way is that each complex is
composed of many proteins and we only analyzed one for each complex. Additionally,
we are measuring protein expression; this does not ensure that proteins are assembled
correctly and that the complex is functioning properly.
Similarly, an increase in ETC protein expression does not necessarily mean an
increase in respiration. Respiration is a tightly controlled process. Potential ATP
production and oxygen consumption capacity could be much greater than what is
measured at basal levels. The observed increase in ETC protein expression may
represent potential functioning of the ETC chain. For example, after strenuous exercise
oxygen consumption and ATP production could be three times what it was at rest
without any increase in mitochondrial mass. Uncoupling the proton gradient with FCCP
showed maximal oxygen consumption but says nothing about ATP synthesis. Future
studies to investigate this may compare ATP generation between hNSCs and motor
neurons.
In summary, this series of studies suggest that some, but not all, mitobiogenesis
processes increase with motor neuron differentiation of hNSCs. There may be
differences in the timing of gene expression hESC- vs. iPSC-derived cells but it appears
that both cell types decrease glycolysis and increase ETC protein expression without a
change in mitochondrial mass during motor neuron differentiation. One process that the
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current studies do not address is mitochondrial autophagy (mitophagy). Mitophagy is
the cellular process that degrades dysfunctional mitochondria. This process could play a
crucial role in the differentiation process and future studies could explore this.

6.3 Electrical maturation of hPSC-derived motor neurons
The aim of the last series of studies was to investigate the change in electrical
properties of cells as they differentiated into motor neurons. Capacitance (Cm) was
substantially lower in hNSC motor neurons (14.88 ± 1.42 pF in hESC-derived and 9.75
± 0.45 pF in iPSC-derived) than rat spinal motor neurons at days 15-16 of gestation
(E15-16; birth is E21-22; Cm = 29.3 ± 1.0 pF) [39]. Similarly, resting membrane potential
was more depolarized (-39 ± 3.84 mV in hESC-derived and -31.6 ± 4.82 in iPSCderived) than in E16 rat motor neurons (-49.3 ± 5.9 mV) [38]. Since Cm increases and
Vm decreases with motor neuron maturation this may suggest that these cells are still
very early in development and that later time points may reveal characteristics of more
mature cells.
Similarly, sodium channel density was lower than what is seen in embryonic day 4
(E4) chick spinal motor neurons (-29.10 ± 8.29 pA/pF in hESC0-derived and -37.51 ±
5.39 pA/pF in iPSC-derived compared to ~70 pA/pF E4). Potassium channel density is
lower in hESC-derived motor neurons (29.55 ± 9.25 pA/pF) than in embryonic day 4
(E4) chick spinal motor neurons (~65 pA/pF) but iPSC-derived motor neurons showed
similar values (78.91 ± 8.04 pA/pF). Previous studies suggest that both current densities
increase with motor neuron maturation so future studies may wish to investigate these
properties in cells that were differentiated longer. There was a lot of variability in the
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mean peak inward and outward currents, consistent with varying rates of maturation.
Assessing later time points may also result in a greater similarity in maximal currents.
Action potentials were seen on D28 with threshold and rheobase values similar to a
previous study [40]. The fact that some iPSC-derived cells fired action potentials in
response to hyperpolarizing current injection is unusual and may be due to a number of
factors, including rebound depolarization (Ih) that reached threshold. Future studies are
planned to confirm this finding as well as to investigate repetitive action potential firing.

6.5 Use of hPSC-derived motor neurons for disease modeling
One potential use of patient iPSC-derived motor neurons is their use in modeling
disease. If these cells replicate disease pathology they may be useful for testing
promising drug compounds. Both hESC- and iPSC-derived motor neurons from this
study have been used in preliminary studies to test molecules that mimic the
neurotrophins, nerve growth factor (NGF) and brain-derived neurotrophic factor (BDNF).
Neurotrophins promote neuronal growth and survival, but their structure does not allow
them to pass the blood brain barrier (BBB) [141]. Dr. Achilleas Gravanis developed
small molecules, called microneurotrophins, and three analogues were kindly provided
for our studies. Unlike NGF and BDNF, microneurotrophins can pass the BBB. After
hESC-derived motor neurons were treated with 100 nM of the three neurotrophin
analogues, NGF, or vehicle control for four or 24 hours RNA was isolated and sent for
microarray screening. Gene expression analysis was then performed to identify which of
the three compounds activated pathways most similar to NGF. The BNN124 analogue
most closely resembled NGF at both 4 and 24 hours. Based on these promising results,
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we treated hESC- and iPSC-derived motor neurons with the three analogues, NGF,
BDNF, or vehicle control for 24 hours and isolated RNA for RNA-sequencing (RNAseq). RNA-seq data will be analyzed in the coming months and the findings will be
published soon after. Both RNA-seq and microarray analyze gene expression; however,
RNA-seq has a number of advantages. One advantage of RNA-seq is that it can detect
very low expressing genes because it quantitates absolute rather than relative
expression. Microarray technology is based on fluorescence and can only detect
expression over baseline. Another advantage of RNA-seq is that it can detect novel
isoforms and mutations because it does not require a known sequence like microarray
does. Microneurotrophins have potential use in many neurodegenerative diseases
including Alzheimer’s disease, Parkinson’s disease, and Huntington’s disease, as well
as in stroke and nerve injury (for a review see [142]).

6.7 Summary and conclusions
In summary, we have demonstrated the ability to differentiate motor neurons
from both hESC- and iPSC- derived cells in three weeks. The hypothesis that
differentiation of human pluripotent stem cells into electrically excitable motor neurons
will result in increased mitochondrial biogenesis was confirmed at multiple levels.
Expression of upstream regulatory genes increased, along with increased transcription
of mtDNA-encoded genes, and increased levels of representative ETC proteins. Despite
these increases, mitochondrial mass remains unchanged. During this time cells develop
voltage-gated currents characteristic of excitable cells and are able to fire action
potentials in response to depolarizing current.
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6.8 Significance and perspectives
The findings from this study have implications in multiple areas. Motor neurons
are lost in a number of other diseases including progressive bulbar palsy, pseudobulbar
palsy, primary lateral sclerosis, progressive muscular atrophy, and spinal muscular
atrophy. Being able to generate motor neurons from patient blood cells may aid in the
development of treatments for these devastating diseases by better understanding
disease mechanisms and having predictive models to test promising compounds. The
current study also sets the stage for looking at mitobiogenesis in other cell types lost in
neurodegenerative disease including Parkinson’s and Alzheimer’s disease. Since
mitochondrial dysfunction is a common theme in many neurodegenerative diseases a
better understanding of how this pathway is regulated may lead to more effective drug
targets. The findings in the present study suggest that PGC-1α acts through a NRF1ERRα mediated pathway to increase mitobiogenesis in hESC-derived cells and this may
represent a target to increase mitobiogenesis. Together, findings from this study provide
the first evidence that iPSCs from blood can differentiate into electrically active motor
neurons and that mitobiogenesis is increased during motor neuron differentiation in both
hESC- and iPSC-derived cells. Future studies are planned to investigate the effects of
microneurotrophins and SK channel activators on the electrical excitability of these stem
cell derived motor neurons.
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